| Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes.Diabetes Obes Metab | PMID 38379002无 PMCID | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.Clin Gastroenterol Hepatol | PMID 38040274无 PMCID | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).J Eur Acad Dermatol Venereol | PMID 38179809无 PMCID | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.J Am Acad Dermatol | PMID 38253129无 PMCID | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.Cancer Chemother Pharmacol | PMID 38278871PMC11043204 | 2024-May | 0.90 | The record is an original result report of a phase III randomized trial with a drug intervention in oncology. However, the primary endpoints of this analysis are pharmacokinetic and pharmacodynamic measures, not the required time-to-event efficacy endpoints (e.g., OS, PFS). Therefore, it does not meet the time-to-event efficacy criterion for inclusion in the Kaplan-Meier digitization cohort. | 待处理 |
| First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.Lancet Respir Med | PMID 38309287无 PMCID | 2024-May | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial.Lancet Respir Med | PMID 38310918无 PMCID | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.Value Health | PMID 38311180无 PMCID | 2024-May | 0.95 | The study is a randomized Phase III trial with a drug intervention and original results, but it does not have a primary or key secondary time-to-event efficacy endpoint. The focus is on establishing a meaningful symptom change threshold, which falls under quality-of-life analysis, not the required time-to-event outcome for inclusion. | 待处理 |
| Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.Gynecol Oncol | PMID 38325276无 PMCID | 2024-May | 0.95 | The record is an original result report from a Phase III randomized trial with a drug intervention, but it focuses on quality-of-life outcomes as a secondary endpoint, not a time-to-event efficacy endpoint required for inclusion. | 待处理 |
| Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.J Allergy Clin Immunol Pract | PMID 38360213无 PMCID | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.Ann Oncol | PMID 38369015无 PMCID | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.Clin Lymphoma Myeloma Leuk | PMID 38369436无 PMCID | 2024-May | 0.90 | The record meets criteria for oncology, human, randomized, Phase III, drug intervention, and original result. However, it is ineligible because the primary and secondary endpoints are not time-to-event efficacy outcomes. The study evaluates molecular response (MR3.0) and quality of life, not OS, PFS, DFS, EFS, RFS, TTP, or any endpoint with Kaplan-Meier or HR analysis. | 待处理 |
| Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.Ann Oncol | PMID 38382875无 PMCID | 2024-May | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Improvement of fatigue in generalised myasthenia gravis with zilucoplan.J Neurol | PMID 38400914PMC11055786 | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).J Neurol | PMID 38418563PMC11055775 | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up.Leukemia | PMID 38418610无 PMCID | 2024-May | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.Lancet Neurol | PMID 38499015无 PMCID | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.Leuk Res | PMID 38499457无 PMCID | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).Am J Clin Dermatol | PMID 38528257PMC11070400 | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies.Clin Exp Nephrol | PMID 38530490PMC11033221 | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.Eur J Cancer | PMID 38537314无 PMCID | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial.Leukemia | PMID 38538861PMC11073960 | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.Lancet Oncol | PMID 38561010无 PMCID | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.Leuk Res | PMID 38564986无 PMCID | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.Lancet Haematol | PMID 38583455无 PMCID | 2024-May | 0.85 | The record is a Phase 3 randomized oncology trial with a drug intervention, but the primary efficacy endpoint (treatment success defined as complete remission on day 56 after allogeneic HSCT) is not a time-to-event endpoint. No time-to-event outcomes (OS, PFS, etc.), Kaplan-Meier curves, or hazard ratios are described in the provided abstract. | 待处理 |
| The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.Nature | PMID 38588696PMC11136660 | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation.Dig Dis Sci | PMID 38594429PMC11098865 | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.Lancet Glob Health | PMID 38614631PMC11027156 | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.Nat Med | PMID 38637636PMC11108772 | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.ESMO Open | PMID 38642472PMC11046044 | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.Neurology | PMID 38669638无 PMCID | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.ESMO Open | PMID 38692082PMC11070798 | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.Lancet Oncol | PMID 38697155无 PMCID | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol | PMID 38697156无 PMCID | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.Cancer Med | PMID 38716626PMC11077338 | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Phase 3 Trial of Dupilumab for People With Chronic Obstructive Pulmonary Disease and Elevated Peripheral Blood Eosinophil Counts.J Allergy Clin Immunol Pract | PMID 38724168无 PMCID | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.ESMO Open | PMID 38744099PMC11108838 | 2024-May | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).ESMO Open | PMID 38744100PMC11108861 | 2024-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A pilot randomised controlled trial of acceptance and commitment therapy for medication decision-making and quality of life in women with breast cancer: The ACTION trial.Psychooncology | PMID 38752788无 PMCID | 2024-May | 0.85 | The study is a randomized, oncology, human trial with a drug intervention (adjuvant endocrine therapy) and reports original pilot results, but it is not a Phase III trial and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary outcomes are patient-reported measures (medication adherence, quality of life, distress, psychological flexibility). | 待处理 |
| Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial.Clin Transl Sci | PMID 38787305PMC11121758 | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.ESMO Open | PMID 38796287PMC11145752 | 2024-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.Postgrad Med | PMID 38814132无 PMCID | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).J Int Med Res | PMID 38818888PMC11143828 | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prolonged mass azithromycin distributions and macrolide resistance determinants among preschool children in Niger: A sub-study of a cluster-randomized trial (MORDOR).PLoS Med | PMID 38709718PMC11073710 | 2024-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.Vaccine | PMID 38575433无 PMCID | 2024-Apr-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)-Haemophilus type b conjugate combined vaccine (DPT-IPV-Hib) in healthy Japanese Infants ≥ 2 and < 43 months of Age: A phase III, multicenter, active controlled, assessor-blinded, randomized, parallel-group study.Vaccine | PMID 38582691无 PMCID | 2024-Apr-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.Sci Rep | PMID 38684712PMC11059267 | 2024-Apr-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial.BMC Med | PMID 38664766PMC11044329 | 2024-Apr-25 | 0.90 | While the study meets many inclusion criteria (Phase III, randomized, human oncology, drug intervention, original result report), it is ineligible for the KM cohort because the primary efficacy endpoint is not a time-to-event measure. The only time-to-event endpoint reported (failure-free survival) appears to be a secondary endpoint, not the pre-specified primary or key secondary time-to-event endpoint required for this cohort. | 待处理 |
| Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.J Crohns Colitis | PMID 37801628PMC11037103 | 2024-Apr-23 | 0.90 | The study is a Phase III randomized drug trial, but it is not in oncology and does not report a time-to-event efficacy endpoint, which are mandatory criteria for inclusion in this cohort. | 待处理 |
| Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.Blood Adv | PMID 38231126PMC11103175 | 2024-Apr-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |